All Posts

A $100M market cap.A $3B opportunity. One catalyst away. Immunic's Phase 3 oral MS drug is the only one of its kind. The market is still pricing the dilution story. We're pricing the science. The market is confused about what happened. In February 2026, Immunic raised $200 million in an oversubscribed private placement led by BVF Partners — one of the most sophisticated healthcare-focused investment firms in the US. The stock fell. Investors saw dilution: 229 million pre-fun

Back-to-back billion-dollar exits in six months. What they tell us about where immunology is heading — and how R¹E finds these opportunities before the market does. Ventyx Biosciences has entered into a definitive agreement to be acquired by Eli Lilly and Company for $1.2 billion . For investors who had been following our work, this outcome is not a surprise. It is a confirmation. Less than six months ago, another company in our coverage — Tourmaline Bio — was acquired by No

Investing in biotechnology can be a thrilling yet daunting endeavor. With rapid advancements in science and technology, the biotech sector offers numerous opportunities for investors. However, the complexities of this field can also lead to significant risks. In this blog post, we will explore effective strategies for navigating biotech investments, ensuring you make informed decisions that align with your financial goals. Understanding the Biotech Landscape Before diving int

In the rapidly evolving world of life sciences, startups face unique challenges when it comes to securing funding and managing capital effectively. With the right capital strategy, these startups can not only survive but thrive in a competitive landscape. This blog post will explore essential strategies for life science startups to navigate their financial journey successfully. Understanding the Capital Landscape Types of Funding Sources Life science startups have access to v